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Abstract
Clomiphene citrate has been traditionally used as the drug of choice in treating women with anovulatory infertility.
In the last decade letrozole, an aromatase inhibitor has emerged as alternative ovulation induction agent. Literature
confirms that letrozole has a definitive role in anovulatory women who have not responded to the clomiphene
therapy. However its role as an alternative to clomiphene as first line therapy continues to be debated. Although it
is probable that the overall benefits of letrozole surpass clomiphene citrate, currently available data does not
confirm this view. There is need for large well-designed trials.
Background
Anovulatory dysfunction is a common problem and is
responsible for about 40% of female infertility. Polycystic
ovarian syndrome (PCOS) remains one of its leading
causes [1]. Using the Rotterdam criteria a clinical diagno-
sis of PCOS is easily reached and most often treatment
can be initiated following a few basic investigations and
exclusion of a male factor problem.
Clomiphene citrate is considered as the drug of choice
for first line treatment of anovulatory dysfunction for a
variety of reasons. It is orally administered, has few side
effects, is easily available and is inexpensive. Although
ovulation rates are in the range of 70-80% the actual
pregnancy rates are significantly lower at around 30-40%
[1,2]. Clomiphene resistance together with side effects
like multi-follicular development and cyst formation are
areas of concern. The desire for an effective alternative
persists.
Letrozole, an aromatase inhibitor, was introduced into
infertility practice in the year 2000 and is regarded as a
second line treatment option, particularly in women
with clomiphene resistance [3,4]. Letrozole has found
acceptance in various clinical situations and the indica-
tions for use have expanded [5,6]. In contrast to clomi-
phene, letrozole at the customary dose of 2.5 mg elicits
a monofollicular response and does not adversely affect
either the endometrium or the cervical mucus, due to
an absence of a peripheral estrogen receptor blockage.
The oft asked question of whether it is better than
clomiphene as a first line treatment option remains
unanswered and a clear answer would have important
clinical implications for infertility specialists.
Clomiphene vs. letrozole: mechanism of action
Clomiphene, a non steroidal compound, structurally
similar to estrogen, blocks estrogenic hypothalamic
receptors, resulting in blinding of the hypothalamus-
pituitary axis to endogenous circulating estrogen. This
in turn triggers release of FSH from the anterior
pituitary following alterations in GnRH pulsatility.
Clomiphene also has peripheral anti estrogenic action at
the level of the endometrium and cervical mucus, partly
explaining the discrepancy in ovulation rates and
pregnancy rates [1].
Letrozole, a selective aromatase inhibitor, prevents the
conversion of androgens to estrogen, thus releasing the
hypothalamo-pituitary axis from the negative feed back of
estrogen, resulting in an increase of FSH secretion from
the anterior pituitary. The accumulated androgens in the
ovary further increase follicular sensitivity to FSH [7].
Importantly, unlike clomiphen citrate, letrozole
is devoid of any anti estrogenic peripheral action. Letro-
zole is also cleared from the circulation more rapidly
due to a shorter half life (48 hours) as compared to
clomiphene citrate which may take up to 2 months due
to its prolonged half life (2 weeks) [8].
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citrate vs letrozole
Several studies have looked at letrozole versus clomi-
phene as first line therapy in anovulatory infertility.
Atay V et al randomized 106 women with PCOS (55/51)
to receive either letrozole (2.5 mgs) or clomiphene citrate
(100 mgs/day) [9]. The ovulation rate (82.4% Vs 63.6%,
P = 0.01) and the clinical pregnancy rate (21.6% vs. 9.1%,
P = 0.03) were significantly higher in the letrozole group
as compared to the clomiphene group with the authors
recommending letrozole as a better first line approach.
Although a randomized trial, details regarding method of
randomization, allocation concealment and sample size
calculation are not available, thus raising concerns regard-
ing reliability.
In another randomized controlled trial (RCT) Bayar U
et al compared letrozole versus clomiphene citrate as a
first line ovulation inducing agents [10]. There was no sig-
nificant difference in either the ovulation rate or the clini-
cal pregnancy rate between the two groups [(65.7% vs
74.7%) and (9.1% vs 7.4%)]. While well designed, the sam-
ple size was calculated using the projected difference in
follicular numbers and estrogen concentrations on the day
of hCG administration. The authors favor use of letrozole
as first line therapy due to comparable clinical pregnancy
rates and the advantage of development of fewer follicles,
thus reducing the risk of multiple pregnancies.
In the largest RCT trial involving 438 women with
PCOS, Badawy et al compared letrozole versus clomi-
phene [11]. Details regarding allocation concealment or
sample size calculation are not mentioned and the
designated primary outcome was the number of devel-
oped follicles, hormone levels and endometrial thickness
on the day of hCG administration. With the ovulation
and pregnancy rates being comparable between the two
groups, the authors concluded that no benefit was
observed with the use of letrozole as first line therapy,
especially since the cost of the drug is comparatively
high. Interestingly the endometrial thickness in the
women who received clomiphene was significantly
higher than in the Letrozole group, (9.2 +- 0.7 Vs 8.1
+-0.2 mm, P = 0.02), which is contrary to the tradition-
ally accepted view (Table 1).
Begum et al studied a different category of women,
recruiting for their RCT women who did not respond to
100 mg of clomiphene [12]. The study group received
7.5 mgs of letrozole while the control group was given
clomiphene citrate at a dose of 150 mg. Not unexpect-
edly, the ovulation rates in the letrozole arm were signif-
icantly higher as compared to the clomiphene arm
(62.5% vs 37.5%). The results of this trial do not help in
answering the specific issue in question, as the cohort of
women studied possibly represent a clomiphene resis-
tant group.
In their meta-analysis, Polyzos et al reviewed the role
of aromatase inhibitors in female infertility, summing up
the presently available literature [13,14]. The pooled
data from 4 randomized trials (Atay et al 2006; Bayar et
al 2006; Sorabvand et al 2006; Sipe et al 2006) involving
265 women with PCOS revealed a significantly higher
live birth rate per patient with aromatase inhibitors as
compared to clomiphene citrate (OR 2.4, 95% CI 1.2-
4.6, P = .011.) [9,10,13,15,16].Only two of the included
studies specifically compared letrozole and clomiphene
as a single agent therapy. Although homogenous, the
included studies were small in numbers. The results of
the largest trial by Badawy et al, which was not included
in the meta-analysis, do not match the conclusion of the
meta-analysis [11,13].
Requena et al in their literature review looked at ran-
domized trials comparing letrozole versus clomiphene as
first line therapy and included four studies (Atay et al
2006; Bayar et al 2006; Sorabvand et al 2006; Badawy et
al 2007) [9-11,15,17]. The ovulation rate for letrozole in
comparison with clomiphene did not differ significantly
(OR 1.7; 95% CI 0.66 - 2.09) nor did the pregnancy rate
Table 1 RCTs comparing letrozole versus clomiphene as first line for anovulatory women
Sl
no
Authors Study
design
Treatment
arms
Numbers
cycles
Endometrial
thickness
(mm)
Ovulation
rates (%)
Pregnancy
rates (%)
1 Atay V et al.
[9]
Turkey,
2006
RCT Letrozole
2.5 mg vs.
Clomiphene
100 mg
51
vs.
55
8.4 +/- 1.8
vs.
5.2 +/- 1.2
82.4
vs.
63.6
21.6
vs.
9.1
2 Bayar U et al.
[10]
Turkey,
2006
RCT Letrozole
2.5 mg vs.
Clomiphene
100 mg
99
vs.
95
8#
vs.
8#
65.7
vs.
74.7
9.1
vs.
7.4
3 Badawy A et al.
[11]
Egypt,
2009
RCT Letrozole
5 mg vs.
Clomiphene
100 mg
540
vs.
523
8.1+/-0.2
vs.
9.2+/-0.7
67.5
vs.
70.9
15.1
vs.
17.9
# Values represent median
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results need to be interpreted cautiously since the stu-
dies included were not statistically homogenous (I
2
>50%).
A review of the clinical trial registry indicates that sev-
eral trials reviewing the role of letrozole as an ovulatory
inducing agent are underway and hopefully these will
help in arriving at firmer conclusions [18].
Clomiphene resistance
The options for women not responding to increasing
doses of clomiphene include insulin sensitizers, gonado-
trophins, or laparoscopic ovarian drilling [19,20]. Mitw-
a l l ya n dC a s p e ri nan o nr a n domized study evaluated
letrozole as an alternative and obtained an ovulation
rate of 75% [3].
In an RCT comparing letrozole versus anastrazole in
clomiphene resistant women Al Omari et al achieved an
ovulation rate of 84% while Elnashar et al in a compara-
tive study obtained an ovulation rate of 54% using letro-
zole [4,21]. We conducted a randomized double blind
placebo controlled trial using letrozole 2.5 mgs in clomi-
phene resistant women and obtained an ovulation rate
of 33.3% [22]. The discrepancy in the ovulation rates
could be attributed to either the dose of the drug cho-
sen or to the small numbers studied. An expected
response would be in the range of 30-50% in this group
of women. Letrozole was used as an adjunct for breast
cancer treatment at a dose 2.5 mgs. A similar dose was
followed for ovulation induction.
Al Fahidi et al, looking at different dosage schedules
(5 mgs vs. 2.5 mgs), found a significant increase in the
number of mature follicles and the pregnancy rate/cycle
with a dose of 5 mg. No multiple pregnancies were
recorded in either group [23].
Summing up, Letrozole appears to an effective ovula-
tion inducing agent in women with clomiphene resis-
tance, though dosing issues still need to be resolved.
Clomiphene failure
Quentero et al looked at the options available for
women who failed to conceive despite ovulation follow-
ing clomiphene therapy (clomiphene failure) [24]. In a
small group of such women they compared letrozole
versus gonadotrophins and obtained significantly higher
pregnancy rates with gonadotrophins (28% vs. 9%).
There were 2 multiple pregnancies in the gonadotrophin
group as compared to none in the letrozole group. In
comparison to gonadotrophins, letrozole is less expen-
sive and requires less intense cycle monitoring, thus
making it an option for women with clomiphene failure.
Looking at the data from a different angle, additional
pregnancies achieved in this group (CC failure) and in
clomiphene resistant women, could be a possible
explanation for the higher pregnancy rates obtained
using letrozole as a first line in one of the earlier study
[9]. One can always argue that the reverse could also be
true: a group of anovulatory women with letrozole fail-
ure/resistance who may respond to clomiphene. Cur-
rently we do not have data to substantiate this
argument. However first line use of letrozole will even-
tually generate information to answer such questions.
Time to pregnancy
An issue of great importance to couples seeking inferti-
lity treatment is the time to pregnancy. Clinicians
usually follow a step ladder approach in advising treat-
ment: starting with the simplest and least expensive
mode of therapy and then moving higher as required.
However in certain clinical situations like advanced
female age or severe endometriosis starting at a higher
level would be more appropriate.
When clomiphene citrate is used as first line therapy
in anovulatory women one can expect a 25% incidence
of clomiphene resistance. It has been established that
although ovulation rates are in the range of 75% only
30-40% will actually conceive [1]. Hence about 60-65%
of anovulatory women being treated with clomiphene
will fall into either the resistant or failure group. How-
ever, conventionally one starts with a lower dose of clo-
miphene citrate, gradually building up the dose. Hence a
diagnosis of either of these conditions is arrived at only
after several months of therapy. Letrozole has been
shown to be effective in women with either clomiphene
resistance or failure [4,24]. As pointed out by R. Casper
using letrozole as first line therapy would logically help
women bypass these problems thus avoiding superfluous
treatment cycles, which would be especially useful in
older women [25]. Intangible benefits are difficult to
quantify or document but nevertheless are of impor-
tance to couples.
Letrozole has now been in use as an ovulation induc-
tion agent for more than a decade. Even though emer-
ging evidence suggests that it is an effective ovulation
induction agent, comparable if not better than clomi-
phene, it has still not gained universal acceptance for a
variety of reasons. An abstract presentation at ASRM
2005 suggested an increase in congenital malformations
following letrozole treatment. The attention generated
by this publication resulted in the manufacturers
(Novartis) declaring that use of letrozole as an ovulation
induction agent is contraindicated [26]. These observa-
tions were critically analyzed by Tulandi et al who pre-
sented additional data, assuaging fears regarding safety
of letrozole [27].
However the worries and concerns continue and today
letrozole has still not received approval for use in ferti-
lity treatment in the United States, Europe and many
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tory women access to a less expensive, simpler and
effective treatment option, it has lead to a dearth of well
designed trials assessing its role in infertility. Though
some evidence is currently available larger well designed
trials are required to pave the way forward for wider
use.
Conclusions
T oc o n c l u d el e t r o z o l eh a sad e f i n i t i v er o l et op l a yi n
women with either clomiphene failure or resistance.
Currently available data comparing clomiphene and
letrozole as a first line therapy for women with anovula-
tion is conflicting in nature and inconclusive. It is possi-
ble that the overall benefits of letrozole may surpass
clomiphene citrate as it could be beneficial in a sub-
group of women who may not successfully respond to
clomiphene either due to resistance or failure. However
there is need for larger well designed randomized trials
to generate robust data in order to establish the true
potential of letrozole.
Authors’ contributions
Both the authors MSK and KG conceived the report, drafted the manuscript,
designed the Table, and carried the literature search. Both authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 December 2010 Accepted: 21 June 2011
Published: 21 June 2011
References
1. Homburg R: Clomiphene citrate - end of an era? A mini review. Hum
Reprod 2005, 20:2043-2051.
2. Gysler M, March CM, Mishell DR Jr, Bailey EJ: A decades experience with
an individualized clomiphene treatment regimen including its effect on
the post coital test. Fertil Steril 1982, 37:161.
3. Mitwally MFM, Casper RF: Use of an aromatase inhibitor for induction of
ovulation in patients with an inadequate response to clomiphene
citrate. Fertil Steril 2001, 75:305-309.
4. Al-Omari WR, Sulaiman W, Al-Hadithi N: Comparision of two aromatase
inhibitors in women with Clomiphene resistant polycystic ovary
syndrome. Int J Gynecol Obstet 2004, 85:289-291.
5. Azim A, Oktay K: Letrozole for ovulation induction and fertility
preservation by embryo cryopreservation in young women with
endometrial carcinoma. Fertil Steril 2007, 88:657-664.
6. Goswami SK, Das T, Chattopadhyay R, Sawney V, Kumar J, Choudhary K,
Chakravarthy BN, Kabir SN: A randomized single - blind controlled trial of
letrozole as a low cost IVF protocol in women with poor ovarian
response: a preliminary report. Hum Reprod 2004, 19:2031-2035.
7. Holzer H, Casper R, Tulandi T: A new era in ovulation induction. Fertil Steril
2006, 85:277-284.
8. Young SL, Opashi MS, Fritz MA: Serum concentration of euclomiphene
and zuclomiphene across consecutive cycles of clomiphene citrate
therapy in anovulatory infertile women. Fertil Steril 1999, 71:639-644.
9. Atay V, Cam C, Muhcu M, Cam M, Karateke A: Comparision of Letrozole
and Clomiphene citrate in women with polycystic ovaries undergoing
ovarian stimulation. J Int Med Res 2006, 34:73-76.
10. Bayar U, Basavan M, Coskun A, Gezer S: Use of an aromatase inhibitors in
Patient with polycystic ovary syndrome: a prospective randomized trial.
Fertil Steril 2006, 86:1447-1451.
11. Badawy A, Abdul Aal I, Abulatta M: Clomiphene citrate or Letrozole in
women polycystic ovarian syndrome: a prospective randomized trial.
Fertil Steril 2009, 92:849-852.
12. Begum Rashida M, Ferdous J, Begum A, Quadir E: Comparison of efficacy
or aromatase inhibitor and clomiphene citrate in polycystic syndrome.
Fertil Steril 2009, 92:853-857.
13. Polyzos N, Tsappi M, Mauri D, Atay V, Corinovis I, Casazza G: Aromatase
Inhibitors for infertility in polycystic ovary syndrome. The beginning or
the end of a new era? Fertil Steril 2008, 89:278-280.
14. Polyzos N, Tzioras S, Badawy AM, Valachis A, Dritsas C, Mauri D: Aromatase
Inhibitors for female infertility: a systemic review of the literature. Reprod
Biomed Online 2009, 19:456-471.
15. Sohrabvand F, Ansari S, Bagheri M: Efficacy of combined metformin -
letrozole in comparison with metformin - clomiphene citrate in
clomiphene resistant infertile women with polycystic ovarian disease.
Hum Reprod 2006, 21:1432-1435.
16. Sipe CS, Davis WA, Maifeld M, Van Voorhis BJ: A prospective randomized
trial comparing anastrozole and clomiphene citrate in an ovulation
induction protocol using gonadotrophins. Fertil Steril 2006, 86:1676-1681.
17. Requena A, Herroro J, Landeras J, Navarro E, Neyro JL, Salvador C, Tur R,
Callejo J, Checa MA, Farre M, Espinos JJ, Fabregues F, Grana-Barcia M:
Reproductive Endocrinology Interest Group of the Spanish Society of
Fertility: Use of letrozole in assisted reproduction: systemic review and
metanalysis. Hum Reprod Update 2008, 14:571-582.
18. ClinicalTrials.gov. [http://www.clinicaltrials.gov/].
19. George SS, George K, Irwin C, Job V, Selvakumar R, Jeyaseelan V,
Seshadri MS: Sequential treatment of metformin and clomiphene citrate
in clomiphene resistant women with polycystic ovary syndrome: a
randomized controlled trial. Hum Reprod 2003, 18:299-304.
20. Amer SA, Li TC, Metwally M, Emarh M, Ledger WL: Randomized controlled
trial comparing laparoscopic ovarian drilling with clomiphene citrate as
a first line of ovulation induction in women with polycystic ovary
syndrome. Hum Reprod 2009, 24:219-225.
21. Elnashar A, Fouad H, Eldosky M, Saeid N: Letrozole induction of ovulation
in women with clomiphene citrate-resistant polycystic ovary syndrome
may not depend on the period of infertility,the body mass index, or the
luteinizing hormone/follicle-stimulating hormone ratio. Fertil Steril 2006,
85:511-513.
22. Kamath MS, Aleyamma TK, Chandy A, George K: Aromatase inhibitors in
women with clomiphene resistance: a randomized double blind placebo
controlled trial. Fertil Steril 2010, 94:2857-2859.
23. Al-Fadhili R, Sylvestre C, Buckette W, Tan LS, Tulandi T: A randomized trial
of super ovulation with two different doses of letrozole. Fertil Steril 2006,
85:161-164.
24. Quentero RB, Urban R, Lathi RB, Westphal LM, Dahan MH: A comparison of
letrozole to gonadotrophins for ovulation induction, in subjects who
failed to conceive with clomiphene citrate. Fertil Steril 2007, 88:879-885.
25. Casper RF: Letrozole versus clomiphene citrare: which is better for
ovulation induction? Fertil Steril 2009, 92:858-859.
26. Biljan MM, Hemming R, Brassard N: The outcome of 150 babies following
treatment with letrozole or letrozole with gonadotrophins. Fertil Steril
2005, 84(Supp 1):O-231, Abstract-1033.
27. Tulandi T, Martin J, Al-Fadhli R, Kabli N, Forman R, Hitkari J, Librach C,
Greenblatt E, Casper RF: Congenital malformations among 911 newborns
conceived after infertility treatment with letrozole or clomiphene citrate.
Fertil Steril 2006, 85:1761-1765.
doi:10.1186/1477-7827-9-86
Cite this article as: Kamath and George: Letrozole or clomiphene citrate
as first line for anovulatory infertility: a debate. Reproductive Biology and
Endocrinology 2011 9:86.
Kamath and George Reproductive Biology and Endocrinology 2011, 9:86
http://www.rbej.com/content/9/1/86
Page 4 of 4